AZ: No plans for follow up on Brilinta-aspirin link

AstraZeneca doesn't plan to conduct a clinical trial to confirm that aspirin dosage caused a geographic discrepancy in the performance of its newly approved heart drug Brilinta. Some analysts had speculated such a trial might strengthen the image of the brand in the U.S., even though the company has not been asked to do so by regulators. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.